Replies to post #227914 on Biotech Values

[DewDiligence]

SBPH -24% on formal termination of HBV program:

https://finance.yahoo.com/news/spring-bank-discontinues-development-inarigivir-133010840.html

Spring Bank Pharmaceuticals…today announced that it has discontinued development of inarigivir soproxil, which was in Phase 2 development for the treatment of chronic hepatitis B virus (HBV). This decision was made in the interest of patient safety based on the occurrence of unexpected serious adverse events, including one patient death, in Spring Bank’s Phase 2b CATALYST trial.

I’m surprised at the magnitude of today’s sell-off given that Inarigivir was already on life support following the halting of patient dosing one month ago (#msg-152982734).

I never thought much of the Inarigivir program (#msg-148213028).